By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – MDxHealth today said that it has licensed to Takara Bio non-exclusive worldwide rights to its methylation-specific PCR technology.

Japan-based Takara has licensed the technology for the scientific research market. In exchange, MDxHealth will receive an upfront fee and royalties on sales of products incorporating the MSP technology. The firms did not disclose additional terms.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.